Showing papers in "The Lancet Gastroenterology & Hepatology in 2022"

TL;DR: In this article , a systematic review and meta-analysis was carried out to predict the burden of NAFLD by examining and estimating the temporal trends of its worldwide prevalence and incidence.

TL;DR: In this article , a literature review, Delphi process, and mathematical modelling were used to estimate hepatitis C virus (HCV) prevalence (viraemic infection, defined as HCV RNA-positive cases) and the cascade of care among people of all ages (age ≥ 0 years from birth) for the period between Jan 1, 2015 and Dec 31, 2030.

TL;DR: In this paper , the global, regional, and national prevalence of hepatitis B virus (HBV), as well as mortality and disability-adjusted life-years (DALYs) due to HBV, as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 were estimated.

TL;DR: In this article , the authors endorse both the name metabolic (dysfunction)-associated fatty liver disease (MAFLD) as an overarching term and its definition for fatty liver diseases associated with metabolic dysregulation.

TL;DR: Gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety in patients with advanced biliary tract cancer as mentioned in this paper , and patients were not masked to the treatment group.

TL;DR: The authors in this paper examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades.

TL;DR: In this paper , the authors reported that no common environmental exposures have been found, and an infectious agent remains the most plausible cause of severe acute hepatitis in the UK, Europe, USA, Israel, and Japan.

TL;DR: In this paper , the effects of COVID-19 vaccine-induced antibody responses were found in patients with inflammatory bowel disease (IBD) on commonly used immunosuppressive drugs.

TL;DR: In this article , a comprehensive review on the topic of early-onset colorectal cancer, including examining the epidemiology and clinical and pathological features, genetic and epigenetic landscapes, and emerging data on the clinical risk factors associated with this malignancy are also presented.

TL;DR: The prevalence of chronic HBV infection declined over time, particularly in children younger than 5 years, since the introduction of hepatitis B vaccination, andHBV-related death rates also decreased, but HBV- related death counts increased as a result of population growth, ageing, and cohort effects.

TL;DR: In this article , the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma was evaluated in a single-centre, randomised, open-label, phase 2 trial.

TL;DR: Lower anti-SARS-CoV-2 spike protein antibody concentrations were independently associated with infliximab, and multivariable modelling showed no significant differences between patients treated with thiopurine monotherapy and patients with IBD on commonly used immunosuppressive drugs.

TL;DR: In this article , the authors investigated the efficacy and safety of single-agent PD-1 blockade with toripalimab, with or without the COX-2 inhibitor celecoxib, as neoadjuvant treatment for mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer.

TL;DR: The increase in incidence rates in people younger than 50 years and the fast-rising burden in low SDI and middle SDI countries in Asia and Africa calls for colorectal cancer prevention approaches, greater awareness, and cost-effective screening and therapeutic options in these regions.

TL;DR: In this article , the authors evaluated the clinical activity of neoadjuvant cemiplimab (an anti-PD-1) in patients with resectable hepatocellular carcinoma.

TL;DR: The Crohn's disease exclusion diet (CDED) with partial enteral nutrition is effective for induction of remission in children with mild-to-moderate Crohn disease as discussed by the authors .

TL;DR: In this article , an overview of the current data that highlight an association between ultra-processed food consumption and various chronic diseases, with a focus on epidemiological evidence and mechanistic insights involving the intestinal microbiota.

TL;DR: In this paper , the risk of alcohol relapse after transplantation in the early transplantation group compared with the standard transplant group using the alcohol timeline follow back (TLFB) method and a prespecified non-inferiority margin of 10%.

TL;DR: In this article , a systematic review and meta-analysis was conducted to report the prevalence of NAFLD, non-alcoholic fatty liver (NAFL), and non-altaltic steatohepatitis (NASH) in the overweight and obese population.

TL;DR: In this article , the authors compared surgical quality and long-term oncological outcomes of robotic and conventional laparoscopic surgery in patients with middle and low rectal cancer, and reported the short-term outcomes of this trial.

TL;DR: The GARDENIA trial as discussed by the authors compared the safety and efficacy of etrolizumab with infliximab in patients with moderately to severely active ulcerative colitis.

TL;DR: In this article , a systematic review and meta-analysis was conducted to assess the efficacy of interventions to improve hepatitis C virus (HCV) antibody testing, HCV RNA testing, linkage to HCV care, and treatment initiation.

TL;DR: Odevixibat, an ileal bile acid transporter inhibitor, versus placebo in children with progressive familial intrahepatic cholestasis (PFIC) was evaluated in this article .

TL;DR: The STARDUST trial as mentioned in this paper evaluated whether a treat-to-target strategy with early endoscopy, regular biomarker and clinical symptom monitoring, and dose intensification for persistent inflammatory activity, was more successful in achieving endoscopic improvement at week 48 than a clinically driven maintenance strategy in patients with moderate-to severe active Crohn's disease receiving ustekinumab.

TL;DR: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody as discussed by the authors , which has been shown to significantly improve clinical remission relative to placebo in patients with moderately to severely active ulcerative colitis.

TL;DR: The ESCAC-5f trial as mentioned in this paper evaluated the feasibility and efficacy of three different types of short-course neoadjuvant therapy compared with immediate surgery in patients with borderline resectable pancreatic adenocarcinoma.

TL;DR: This paper evaluated the efficacy and safety of pembrolizumab 200 mg intravenously every 3 weeks for 2 years, or until disease progression, unacceptable toxicity, investigator's decision to withdraw the patient from the study, or withdrawal of patient consent.